Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11,704.00 GBX | -0.71% |
|
-0.83% | +11.81% |
02:06am | Fat, not muscle: drugmakers in race for next weight-loss breakthrough | RE |
10:20pm | ASTRAZENECA : Buy rating from JP Morgan | ZD |
Capitalization | 231B 222B 209B 183B 328B 20,041B 364B 2,480B 926B 8,371B 865B 847B 34,965B | P/E ratio 2025 * |
22.9x | P/E ratio 2026 * | 19.7x |
---|---|---|---|---|---|
Enterprise value | 250B 240B 226B 198B 355B 21,687B 393B 2,684B 1,002B 9,058B 936B 917B 37,837B | EV / Sales 2025 * |
4.35x | EV / Sales 2026 * | 3.98x |
Free-Float |
96.62% | Yield 2025 * |
2.16% | Yield 2026 * | 2.28% |
Last Transcript: AstraZeneca PLC
1 day | -0.81% | ||
1 week | -0.83% | ||
Current month | +3.17% | ||
1 month | +8.43% | ||
3 months | +16.76% | ||
6 months | -10.31% | ||
Current year | +11.81% |







Manager | Title | Age | Since |
---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01/10/2012 |
Aradhana Sarin
DFI | Director of Finance/CFO | 51 | 01/08/2021 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/01/2020 |
Director | Title | Age | Since |
---|---|---|---|
Director/Board Member | 69 | 06/04/1999 | |
Pascal Soriot
BRD | Director/Board Member | 64 | 01/10/2012 |
Philip Broadley
BRD | Director/Board Member | 64 | 27/04/2017 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
8.29% | 59 M€ | +4.74% | - | |
5.39% | 209 M€ | +5.31% | ||
5.17% | 33 M€ | +3.72% | - | |
4.89% | 610 M€ | +9.40% |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-0.71% | -0.83% | +12.34% | +27.91% | 231B | ||
+1.11% | -0.71% | +14.70% | +262.46% | 772B | ||
+1.79% | +1.69% | +0.02% | -2.02% | 373B | ||
+1.79% | +2.01% | -30.36% | +83.59% | 366B | ||
+0.46% | +2.20% | +12.23% | +35.50% | 346B | ||
-0.07% | +1.03% | +27.03% | -13.20% | 263B | ||
+2.65% | -0.12% | -32.82% | +12.67% | 211B | ||
+0.44% | -1.24% | +7.85% | +22.53% | 211B | ||
+0.51% | -0.27% | +3.80% | +32.91% | 157B | ||
+0.88% | +1.53% | -6.27% | -45.59% | 145B | ||
Average | +0.85% | -0.47% | +0.85% | +41.68% | 307.37B | |
Weighted average by Cap. | +0.95% | -0.46% | +2.88% | +82.52% |
2025 * | 2026 * | |
---|---|---|
Net sales | 57.32B 55.07B 51.86B 45.59B 81.53B 4,981B 90.37B 616B 230B 2,080B 215B 211B 8,690B | 60.73B 58.35B 54.95B 48.3B 86.38B 5,278B 95.75B 653B 244B 2,204B 228B 223B 9,207B |
Net income | 10B 9.61B 9.05B 7.95B 14.22B 869B 15.76B 108B 40.12B 363B 37.48B 36.72B 1,516B | 11.81B 11.35B 10.69B 9.39B 16.8B 1,027B 18.62B 127B 47.41B 429B 44.28B 43.39B 1,791B |
Net Debt | 18.94B 18.2B 17.14B 15.06B 26.94B 1,646B 29.86B 204B 76.01B 687B 70.99B 69.56B 2,871B | 11.31B 10.87B 10.23B 9B 16.09B 983B 17.83B 122B 45.4B 411B 42.4B 41.54B 1,715B |
Date | Price | Change | Volume |
---|---|---|---|
20/02/25 | 11,704.00 p | -0.71% | 1,261,683 |
18/02/25 | 11,788.00 p | +0.63% | 1,256,095 |
17/02/25 | 11,714.00 p | +0.05% | 719,403 |
14/02/25 | 11,708.00 p | -2.14% | 3,001,390 |
13/02/25 | 11,964.00 p | +1.37% | 4,659,511 |
Delayed Quote London S.E., 20 February 2025 at 03:35 am AEDT
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock

MarketScreener is also available in this country: United States.
Switch edition